Efficacy and safety of regorafenib compared to placebo and to post-cross-over regorafenib in advanced non-adipocytic soft tissue sarcoma. Brodowicz, T.; Mir, O.; Wallet, J.; Italiano, A.; Blay, J. Y.; Bertucci, F.; Eisterer, W.; Chevreau, C.; Piperno-Neumann, S.; Bompas, E.; Ryckewaert, T.; Liegl-Antzwager, B.; Thery, J.; Penel, N.; Le Cesne, A.; Le Deley, M. C.. Eur J Cancer. 2018; 28-36: p.28-36. doi:10.1016/j.ejca.2018.05.008Article
Oncostat